MPS Loria Financial Planners LLC Has $612,000 Stake in Eli Lilly and Company (NYSE:LLY)

MPS Loria Financial Planners LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 42.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 690 shares of the company’s stock after selling 513 shares during the quarter. MPS Loria Financial Planners LLC’s holdings in Eli Lilly and Company were worth $612,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. CGN Advisors LLC boosted its holdings in Eli Lilly and Company by 1.4% in the first quarter. CGN Advisors LLC now owns 1,001 shares of the company’s stock worth $779,000 after acquiring an additional 14 shares in the last quarter. Central Valley Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the 1st quarter worth $245,000. Annex Advisory Services LLC raised its stake in Eli Lilly and Company by 14.1% in the 1st quarter. Annex Advisory Services LLC now owns 4,332 shares of the company’s stock worth $3,370,000 after acquiring an additional 535 shares during the last quarter. Fermata Advisors LLC raised its stake in shares of Eli Lilly and Company by 27.8% during the 1st quarter. Fermata Advisors LLC now owns 1,113 shares of the company’s stock valued at $866,000 after buying an additional 242 shares during the last quarter. Finally, Dynamic Advisor Solutions LLC boosted its holdings in Eli Lilly and Company by 2.8% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,381 shares of the company’s stock worth $11,966,000 after buying an additional 417 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Wells Fargo & Company upped their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Guggenheim raised their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Bank of America raised their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, September 16th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,002.24.

Eli Lilly and Company Stock Down 1.3 %

LLY opened at $906.13 on Tuesday. The company has a market cap of $861.19 billion, a PE ratio of 133.45, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53. The company has a 50-day moving average price of $921.65 and a 200 day moving average price of $859.57.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Sell-side analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.